Doctors Condemn Prediction Markets on Clinical Trial Outcomes, Warning of Threats to Trial Integrity
Kalshi's pilot lets users wager on late-stage trial results. Physicians and researchers say the markets threaten trial ...
Giredestrant plus everolimus significantly outperforms standard endocrine therapy in a post-CDK4/6 inhibitor setting.
Electroacupuncture reduced liver fat and partly restored anti-inflammatory macrophages in mice, offering early signs that ...
Primary care practitioners report that using an AI scribe gives them back much-needed time that some use to see more patients ...
Study reports an AI model is as accurate as humans for generating preliminary echocardiogram interpretations, saving time for ...
By testing procedures, pathogens, and substances on themselves, these researchers generated discoveries that left a lasting ...
Patients can be left with nonmedical expenses that are substantial for them, but a drop in the bucket for trial sponsors.
As of November 15, the long-delayed modifications for the iPLEDGE REMS for the teratogenic acne drug isotretinoin are in ...
An international panel reaches consensus on just 35 of 105 clinical statements on ketamine and esketamine, leaving key ...
After 68 weeks of semaglutide treatment, more than a third of patients with severe obesity, as young as 6 years of age, no longer had a BMI indicative of the disease.
Women’s hormonal transitions remain underrepresented in neuroscience research, despite evidence linking changes in estrogen ...
A survey of nearly 29,000 healthcare workers in France highlights the effects of extreme weather on clinical care, staff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results